IRIS
MANCARDI, GIOVANNI LUIGI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 47.580
Totale 47.580
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 47.580
Totale 47.580
Salva come PNG Salva come JPEG
Città #
Genova 35.457
Genoa 5.024
Rapallo 4.076
Vado Ligure 2.943
Bordighera 80
Totale 47.580
Salva come PNG Salva come JPEG
Nome #
Composite MRI measures and short-term disability in patients with clinically isolated syndrome suggestive of MS 209
Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy 190
A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. 188
An updated Italian normative dataset for the Stroop color word test (SCWT) 184
Association of melanoma and natalizumab therapy in the Italian MS population: a second case report. 177
Neural correlates of ankle movements during different motor tasks: A feasibility study 171
Finger motor performance as a new quantitative clinical endpoint in multiple sclerosis 168
Cord cross-sectional area at foramen magnum as a correlate of disability in amyotrophic lateral sclerosis 168
Basal ganglia are active during motor performance recovery after a demanding motor task. 166
Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. 165
Experimental Charcot-Marie-Tooth type 1A: A cDNA microarrays analysis 164
Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption 163
Fast course ALS presenting with vocal cord paralysis: clinical features, bioinformatic and modelling analysis of the novel SOD1 Gly147Ser mutation. 163
Hereditary motor and sensory neuropathy with myelin outfolding: clinical, genetic and neuropathological study of three cases 162
A normative study of the Italian printed word version of the free and cued selective reminding test 162
Dysimmune mononeuropathies: A diagnosis not to be missed 162
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. 160
Alpha-lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. 160
17p11.2 duplication is a common finding in sporadic cases of charcot-marie-tooth type 1 158
Mechanisms of the adaptive immune response inside the central nervous system during inflammatory and autoimmune diseases. 157
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. 157
Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. 156
Urinary JCV-DNA Testing during Natalizumab Treatment May Increase Accuracy of PML Risk Stratification. 155
Repeated courses of granulocyte colony-stimulating factor in amyotrophic lateral sclerosis: clinical and biological results from a prospective multicenter study. 155
Reliability of clinical outcome measures in Charcot-Marie-Tooth disease. 154
Clinical characteristics of patients with familial amyotrophic lateral sclerosis carrying the pathogenic GGGGCC hexanucleotide repeat expansion of C9ORF72. 153
The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study. 153
The molecular signature of therapeutic mesenchymal stem cells exposes the architecture of the hematopoietic stem cell niche synapse. 153
Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. 153
Early abnormalities in sciatic nerve function and structure in a rat model of Charcot-Marie-Tooth type 1A disease. 152
Evidence for aerobic ATP synthesis in isolated myelin vesicles 152
Acute disseminated encephalomyelitis with severe neurological outcomes following virosomal seasonal influenza vaccine 152
In vitro VLA-4 blockade results in an impaired NK cell-mediated immune surveillance against melanoma 152
Bovine spongiform encephalopathy and Creutzfeldt-Jakob disease: facts and uncertainties underlying the causal link between animal and human diseases 151
Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. 151
Retinal nerve fibre layer measurements and optic nerve head analysis in multiple sclerosis patients. 151
Hereditary motor and sensory neuropathy with deafness, mental retardation and absence of large myelinated fibers. 151
Clinical epidemiology of ALS in Liguria, Italy. 151
Autologous stem cell transplantation as rescue therapy in malignant forms of multiple sclerosis. 150
Clinical epidemiology of amyotrophic lateral sclerosis in Liguria, Italy: An update of LIGALS register 150
Neural correlates of lower limbs proprioception: An fMRI study of foot position matching 150
OXCARBAZEPINE FOR TREATING PAROXYSMAL PAINFUL SYMPTOMS IN MULTIPLE SCLEROSIS: A PILOT STUDY. 149
Granulocyte-macrophage colony-stimulating factor activity in cerebrospinal fluid 149
Three years of experience: the Italian registry and safety data update 149
Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience. 149
Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. 146
Growing Region Segmentation Software (GRES) for quantitative magnetic resonance imaging of multiple sclerosis: intra- and inter-observer agreement variability: a comparison with manual contouring method. 146
Different MRI patterns in MS worsening after stopping fingolimod 146
Development and validation of a patient self-assessed questionnaire on satisfaction with communication of the multiple sclerosis diagnosis. 145
Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis. 144
Direct immunofluorescence in sural nerve biopsies. 144
Relapses after treatment with rituximab in a patient with multiple sclerosis and anti myelin-associated glycoprotein polyneuropathy. 143
ATXN2 is a modifier of phenotype in ALS patients of Sardinian ancestry. 143
Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis. 143
Neurological research in Italy in 2003 and 2004. 142
Charcot-Marie-Tooth (CMT) 1a duplication at 17p11.2 in Italian families. 142
The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study. 141
Stem cells for multiple sclerosis: promises and reality. 141
Underexpression of messenger RNA for peripheral myelin protein 22 in hereditary neuropathy with liability to pressure palsies 141
GFAP expression of human Schwann cells in tissue culture. 141
An engineered glove for investigating the neural correlates of finger movements using functional magnetic resonance imaging 141
Acute axonal form of Guillain-Barre syndrome in a multiple sclerosis patient: chance association or linked disorders? 140
Autologous hematopoietic stem cell transplantation in multiple sclerosis: A phase II trial. 140
A restricted T cell response to myelin basic protein (MBP) is stable in multiple sclerosis (MS) patients. 140
Mycophenolate mofetil in dysimmune neuropathies: a preliminary study. 140
A patient with multiple sclerosis and Down's syndrome with a rare paroxysmal symptom at onset. 139
Anxiety and depression in multiple sclerosis patients around diagnosis. 139
Human mesenchymal stem cells promote survival of T cells in a quiescent state. 139
A prospective study of acute idiopathic neuropathy II antecedent events. 138
A New App for At-Home Cognitive Training: Description and Pilot Testing on Patients with Multiple Sclerosis 138
Hand Rehabilitation Treatment for Charcot-Marie-Tooth Disease: An Open Label Pilot Study 138
A major influence of the T cell receptor repertoire as compared to antigen processing-presentation in the selection of myelin basic protein epitopes in multiple sclerosis. 137
An Italian family with Ala-47 transthyretin mutation associated with cardiomyopathy and polyneuropathy. 136
Mesenchymal stem cells shape microglia effector functions through the release of CX3CL1 136
Selective impairments of motor sequence learning in multiple sclerosis patients with minimal disability 136
Upper limb motor training based on task-oriented exercises induces functional brain reorganization in patients with multiple sclerosis 136
Autologous haematopoietic stem-cell transplantation in multiple sclerosis: benefits and risks 135
'Apraxia' of eye opening in idiopathic Parkinson's disease. 135
The prevalence of multiple sclerosis in the north-west Italian province of Genoa. 134
Early degeneration of the cerebellar cortex, particularly the granular cells. 134
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. 134
The Multiple Sclerosis Knowledge Questionnaire: a self-administered instrument for recently diagnosed patients. 134
Multiple sclerosis: hyperintense dentate nucleus on unenhanced T1-weighted MR images is associated with the secondary progressive subtype 133
Abnormal tau-reactive filaments in olfactory mucosa in biopsy specimens of patients with probable Alzheimer's disease. 133
Schwann cell expression of HLA-DR antigen in peripheral neuropathies. 133
PMP22 transgenic dorsal root ganglia cultures show myelin abnormalities similar to those of human CMT1A. 133
Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. 133
T137A variant is a pathogenetic SOD1 mutation associated with a slowly progressive ALS phenotype. 133
Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. 133
Brain stroke imaging by means of microwave tomography: Quantitative inversion procedure, configuration set up, and preliminary experimental results 133
A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper. 132
Progressive sensory-motor polyneuropathy with tomaculous changes is associated to 17p11.2 deletion. 132
Mesenchymal stem cells for multiple sclerosis: does neural differentiation really matter? 132
Screening, diagnosis, and management of obstructive sleep apnea in dangerous-goods truck drivers: to be aware or not? 132
Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. 132
Accumulation of clonally-related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients 131
Cranial MRI in ataxia-telangiectasia. 131
The D355V mutation decreases EGR2 binding to an element within the Cx32 promoter. 131
Dysregulation of regulatory CD56bright NK cells/T cells interactions in multiple sclerosis 131
Different cellular and molecular mechanisms for early and late-onset myelin protein zero mutations 130
Totale 14.740
Salva come PNG Salva come JPEG
Categoria #
all - tutte 136.096
article - articoli 124.698
book - libri 582
conference - conferenze 9.877
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 939
Totale 272.192
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20205.989 0 0 0 0 0 0 0 931 1.236 2.041 1.244 537
2020/20213.506 275 315 396 372 179 256 196 348 291 384 233 261
2021/20225.493 165 399 656 695 170 292 287 1.250 217 494 152 716
2022/20234.881 491 396 58 467 803 858 20 370 854 27 467 70
2023/20242.539 154 340 64 283 190 521 201 152 131 35 122 346
2024/20254.721 248 564 249 465 989 778 631 797 0 0 0 0
Totale 48.134